NCT00673751Unknown不适用
GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome
Glostrup University Hospital, Copenhagen1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2008年5月7日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 8
- 试验地点
- 1
研究概览
简要总结
The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome
详细描述
previous studies have shown that GLP-2 increases mesenteric blow flow, we wish to examine the effect of subcutaneus GLP-2 on patients with short bowl syndrome. The patients will single blinded been given 450 nmol GLP-2 and isotonic saline in order to act as their own reference.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •clinical diagnose of short bowel syndrome 4 month of stable fase
排除标准
- •activity in IBD
研究组 & 干预措施
2
Placebo Comparator
subcutaneous isotonic saline
干预措施: Placebo (Drug)
1
Active Comparator
subcutaneous GLP-2
干预措施: GLP-2 (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in HumansHealthyNCT00273000Glostrup University Hospital, Copenhagen10
已完成
不适用
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)HealthyNCT06774807University of Copenhagen10
已完成
不适用
Alternation in glucagon secretion by Sodium glucose transporter-2 inhibitorType2 diabetes mellitusType2 deabetes mellitusC18.452.394.750.149JPRN-jRCTs031190010Ichikawa Raishi20
已完成
不适用
GLP-2 (Glucagonlike Peptide-2) and Blood FlowRegional Blood FlowNCT00540215Glostrup University Hospital, Copenhagen15
已完成
4 期
PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to GlucosuriaDiabetes Mellitus, Type 2NCT03168295The University of Texas Health Science Center at San Antonio34